Uplizna 100 mg concentrate for solution for infusion
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Amgen Inc.
Conditions
Autoimmune Hepatitis (AIH)Generalized Myasthenia GravisImmunoglobulin G4 related Disease (IgG4-RD)anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)
Phase 2
A PHASE-2B, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE ACTIVITY AND SAFETY OF INEBILIZUMAB IN ANTI-NMDA RECEPTOR ENCEPHALITIS AND ASSESS MARKERS OF DISEASE (EXTINGUISH)
RecruitingCTIS2023-504686-23-00
Start: 2024-12-10Target: 26Updated: 2025-11-13
A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG)
Not yet recruitingCTIS2025-520993-20-00
Target: 4Updated: 2026-02-11
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)
Not yet recruitingCTIS2025-520988-41-00
Target: 2Updated: 2026-02-25
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
Not yet recruitingCTIS2025-522393-37-00
Target: 49Updated: 2026-09-18